Jitendra – Page 3 – Scilex Holding

23 Sep

David Lemus

March 2, 2024
Posted by Jitendra

Dave Lemus joined as our Director in April 2022. Mr. Lemus was previously the Chief Executive Officer of Ironshore Pharmaceuticals Inc. and serves on the board of directors of Silence Therapeutics, Sorrento Therapeutics,...

23 Sep

Board of Directors

Dorman Followwill

March 2, 2024
Posted by Jitendra

Dorman Followwill was Senior Partner of Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries from...

21 Sep

Board of Directors

Jay Chun, MD, PhD

March 2, 2024
Posted by Jitendra

Jay Chun, M.D., Ph.D., has served as the Chief of Neurosurgery and Director of the Atlantic Health Spine Center at Overlook Medical Center at Atlantic Health System since September 2015. Dr. Chun has...

14 Sep

Publications

Review of Multimodal Therapies for the Treatment of Neuropathic Pain: Clinical Implications

February 17, 2024
Posted by Jitendra

14 Sep

Publications

Impact of Adhesion on Patient Satisfaction, Medication Switching and Discontinuation With Lidocaine Topical Patches Based on FDA Adverse Event Reporting and Patient Surveys

February 15, 2024
Posted by Jitendra

14 Sep

Publications

Decreased Healthcare Resource Utilization With Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

September 14, 2023
Posted by Jitendra

14 Sep

Publications

Pain Freedom With Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose: Post Hoc Analysis in the Acute Treatment of Migraine

September 14, 2023
Posted by Jitendra

05 Jul

Press Release

Scilex Holding Company Generates Record Monthly Revenue In June 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended June 2023, Quarter Ended June 2023, And Year-To-Date As Of June 2023, Based O

July 5, 2023
Posted by Jitendra

16 Jun

Press Release

Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX

June 16, 2023
Posted by Jitendra

16 Jun

Publications

Detection and Adjustment for Participant Response Effects in a 2-Period, Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Oral Solution for the Acute Treatment of Migraine

June 16, 2023
Posted by Jitendra

Posts by Jitendra

David Lemus

Dorman Followwill

Jay Chun, MD, PhD

Review of Multimodal Therapies for the Treatment of Neuropathic Pain: Clinical Implications

Impact of Adhesion on Patient Satisfaction, Medication Switching and Discontinuation With Lidocaine Topical Patches Based on FDA Adverse Event Reporting and Patient Surveys

Decreased Healthcare Resource Utilization With Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Pain Freedom With Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose: Post Hoc Analysis in the Acute Treatment of Migraine

Scilex Holding Company Generates Record Monthly Revenue In June 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended June 2023, Quarter Ended June 2023, And Year-To-Date As Of June 2023, Based O

Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX

Detection and Adjustment for Participant Response Effects in a 2-Period, Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Oral Solution for the Acute Treatment of Migraine

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates